Santoni, Natália, Thaís Melo, Anna Rita Aguirre, Daniela Veiga, e Camila Souza. 2017. “Cost-Effectiveness of Afatinib Versus Pemetrexed Plus Cisplatin, Erlotinib and Gefitinib As First Line Treatment in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor Mutation (EFGR+) Non-Small Cell Lung Cancer in the Brazil”. Jornal Brasileiro De Economia Da Saúde 9 (1):73-82. https://doi.org/10.21115/JBES.v9.n1.p73-82.